Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 1
2018 2
2021 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Your search for Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas retrieved no results
Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas.
Poggio T, Duyster J, Illert AL. Poggio T, et al. Cancers (Basel). 2018 Sep 18;10(9):339. doi: 10.3390/cancers10090339. Cancers (Basel). 2018. PMID: 30231561 Free PMC article. Review.
T cell non-Hodgkin lymphoma (T-NHL) is a rare and heterogeneous group of neoplasms of the lymphoid system. ...In this review, we summarize the currently available clinical evidence for immunotherapy in T-NHL, focusing on the result
T cell non-Hodgkin lymphoma (T-NHL) is a rare and heterogeneous group of neoplasms of the lymphoid system
Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma.
Castaneda-Puglianini O, Chavez JC. Castaneda-Puglianini O, et al. Drugs Context. 2021 Sep 21;10:2021-2-4. doi: 10.7573/dic.2021-2-4. eCollection 2021. Drugs Context. 2021. PMID: 34603459 Free PMC article. Review.
Bispecific antibodies represent a novel immunotherapeutic approach for the treatment of several malignancies, in particular non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). ...Here, we present a narrative review of the most current
Bispecific antibodies represent a novel immunotherapeutic approach for the treatment of several malignancies, in particular …
Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.
Weber ANR, Cardona Gloria Y, Çınar Ö, Reinhardt HC, Pezzutto A, Wolz OO. Weber ANR, et al. Cancer Immunol Immunother. 2018 Nov;67(11):1797-1807. doi: 10.1007/s00262-018-2242-9. Epub 2018 Sep 11. Cancer Immunol Immunother. 2018. PMID: 30203262 Review.
Oncogenic MYD88 mutations, most notably the Leu 265 Pro (L265P) mutation, were recently identified as potential driver mutations in various B-cell non-Hodgkin Lymphomas (NHLs). The L265P mutation is now thought to be common to virtually all NHLs and oc …
Oncogenic MYD88 mutations, most notably the Leu 265 Pro (L265P) mutation, were recently identified as potential driver mutations in various …
Lymphoma of the skin.
Connors JM, Hsi ED, Foss FM. Connors JM, et al. Hematology Am Soc Hematol Educ Program. 2002:263-82. doi: 10.1182/asheducation-2002.1.263. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446427 Review.
This chapter describes the various ways in which the non-Hodgkin's lymphomas can involve the skin, how these diseases should be assessed, standard treatments available in 2002, and new directions in research. ...She includes comments on the newer anti- …
This chapter describes the various ways in which the non-Hodgkin's lymphomas can involve the skin, how these dis …
An array of immunotherapeutic strategies for B-cell lymphomas.
Schultze JL. Schultze JL. Expert Opin Investig Drugs. 1999 Dec;8(12):2059-2071. doi: 10.1517/13543784.8.12.2059. Expert Opin Investig Drugs. 1999. PMID: 11139840
With FDA approval of monoclonal antibodies (mAb) against the B-cell-specific cell surface molecule CD20, immunotherapy in B-cell non-Hodgkin's-lymphomas (NHL) has gained momentum. ...There are several new strategies for vaccination …
With FDA approval of monoclonal antibodies (mAb) against the B-cell-specific cell surface molecule CD20, immunotherapy in B- …
Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma.
Gordon MJ, Sureda A, Westin JR. Gordon MJ, et al. Leuk Lymphoma. 2022 Sep;63(9):2041-2051. doi: 10.1080/10428194.2022.2068007. Epub 2022 May 12. Leuk Lymphoma. 2022. PMID: 35549635
Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma. ...The patients not cured with current chemotherapy-based approaches may benefit from immunotherapy. ...
Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma. ...The patients not c …